bioMerieux (OTCMKTS:BMXMF) Given Consensus Recommendation of “Reduce” by Brokerages

Shares of bioMerieux (OTCMKTS:BMXMF) have been assigned an average rating of “Reduce” from the six ratings firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and five have given a hold rating to the company.

Several research firms recently issued reports on BMXMF. Piper Sandler initiated coverage on bioMerieux in a report on Thursday, June 11th. They issued a “neutral” rating on the stock. UBS Group cut bioMerieux from a “buy” rating to a “neutral” rating in a report on Monday, June 1st. Morgan Stanley downgraded bioMerieux from an “overweight” rating to an “underweight” rating in a research report on Tuesday, June 23rd. Zacks Research raised bioMerieux to a “hold” rating in a research note on Tuesday, April 28th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of bioMerieux in a research report on Wednesday, June 17th.

bioMerieux Stock Performance

BMXMF opened at $80.31 on Friday. bioMerieux has a twelve month low of $77.00 and a twelve month high of $152.00. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.48 and a current ratio of 2.39. The company has a 50-day moving average price of $81.75 and a 200 day moving average price of $100.94.

bioMerieux Company Profile

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.